Skip to content

20-023 - Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Status: open
S1900C - A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)

Treatment for Lung Cancer

Contact Us Or call (251) 445-9834

Description

This is an investigational study of two drugs (talazoparib and avelumab) used in combination to treat a type of lung cancer (non-squamous non-small cell lung cancer [NSCLC]) in patients whose disease has progressed. The goal of this study is to target a mutation that can occur within the cancer cells of some non-squamous NSCLC patients.

Sponsors

This trial is sponsored by National Cancer Institute (NCI).

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.